Usana Health Sciences Free Cash Flow (FCF) History (USNA)
Usana Health Sciences reported $8.5M in free cash flow for fiscal 2025, a decrease of 83.26% from the previous fiscal year, with a free cash flow margin of 0.92%.
View full Usana Health Sciences company overviewUsana Health Sciences free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2026-01-03 | $8.5M | −$42.4M | −83.26% | +0.92% |
| 2024 | 2024-12-28 | $50.9M | −$5.2M | −9.31% | +5.96% |
| 2023 | 2023-12-30 | $56.1M | −$37.4M | −39.95% | +6.10% |
| 2022 | 2022-12-31 | $93.5M | −$15.0M | −13.79% | +9.36% |
| 2021 | 2022-01-01 | $108.5M | −$36.8M | −25.36% | +9.14% |
| 2020 | 2021-01-02 | $145.3M | $35.1M | +31.90% | +12.81% |
| 2019 | 2019-12-28 | $110.2M | −$30.5M | −21.70% | +10.38% |
| 2018 | 2018-12-29 | $140.7M | $30.1M | +27.26% | +11.83% |
| 2017 | 2017-12-30 | $110.6M | $6.4M | +6.11% | +10.56% |
| 2016 | 2016-12-31 | $104.2M | $16.5M | +18.76% | +10.36% |
| 2015 | 2016-01-02 | $87.7M | $3.0M | +3.51% | — |
| 2014 | 2015-01-03 | $84.8M | −$6.1M | −6.69% | — |
| 2013 | 2013-12-28 | $90.8M | $6.5M | +7.67% | — |
| 2012 | 2012-12-29 | $84.4M | $24.9M | +41.89% | — |
| 2011 | 2011-12-31 | $59.5M | −$2.5M | −3.96% | — |
| 2010 | 2011-01-01 | $61.9M | $33.6M | +118.47% | — |
| 2009 | 2010-01-02 | $28.3M | — | — | — |
Usana Health Sciences quarterly free cash flow
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-07-04 | $20.2M | $13.0M | +180.41% | +9.03% |
| Q1 2026 | 2026-04-04 | $7.1M | −$5.6M | −43.89% | +2.84% |
| Q4 2025 | 2026-01-03 | −$6.2M | −$10.2M | — | −2.73% |
| Q3 2025 | 2025-09-27 | −$5.2M | −$32.3M | — | −2.41% |
| Q2 2025 | 2025-06-28 | $7.2M | $1.9M | +35.19% | +3.05% |
| Q1 2025 | 2025-03-29 | $12.7M | −$1.8M | −12.45% | +5.08% |
| Q4 2024 | 2024-12-28 | $4.0M | −$14.7M | −78.70% | +1.86% |
| Q3 2024 | 2024-09-28 | $27.1M | $6.4M | +30.58% | +13.55% |
| Q2 2024 | 2024-06-29 | $5.3M | −$623,000 | −10.48% | +2.50% |
| Q1 2024 | 2024-03-30 | $14.5M | $3.8M | +35.02% | +6.36% |
| Q4 2023 | 2023-12-30 | $18.7M | −$18.5M | −49.70% | +8.46% |
| Q3 2023 | 2023-09-30 | $20.8M | −$4.8M | −18.65% | +9.74% |
| Q2 2023 | 2023-07-01 | $5.9M | −$6.9M | −53.82% | +2.49% |
| Q1 2023 | 2023-04-01 | $10.7M | −$7.2M | −40.12% | +4.32% |
| Q4 2022 | 2022-12-31 | $37.2M | $15.4M | +70.78% | +16.31% |
| Q3 2022 | 2022-10-01 | $25.5M | −$5.5M | −17.66% | +10.95% |
| Q2 2022 | 2022-07-02 | $12.9M | −$24.7M | −65.79% | +4.87% |
| Q1 2022 | 2022-04-02 | $17.9M | −$150,000 | −0.83% | +6.56% |
| Q4 2021 | 2022-01-01 | $21.8M | −$24.7M | −53.12% | +8.14% |
| Q3 2021 | 2021-10-02 | $31.0M | −$15.2M | −32.95% | +11.31% |
| Q2 2021 | 2021-07-03 | $37.6M | $8.5M | +29.32% | +11.17% |
| Q1 2021 | 2021-04-03 | $18.1M | −$5.5M | −23.21% | +5.86% |
| Q4 2020 | 2021-01-02 | $46.4M | −$4.1M | −8.14% | +14.95% |
| Q3 2020 | 2020-09-26 | $46.3M | $201,000 | +0.44% | +15.50% |
| Q2 2020 | 2020-06-27 | $29.1M | $18.5M | +174.24% | +11.23% |
| Q1 2020 | 2020-03-28 | $23.5M | $20.6M | +698.91% | +8.82% |
| Q4 2019 | 2019-12-28 | $50.5M | $12.7M | +33.52% | +18.63% |
| Q3 2019 | 2019-09-28 | $46.1M | −$6.2M | −11.86% | +17.68% |
| Q2 2019 | 2019-06-29 | $10.6M | −$23.4M | −68.80% | +4.14% |
| Q1 2019 | 2019-03-30 | $2.9M | −$13.6M | −82.23% | +1.08% |
| Q4 2018 | 2018-12-29 | $37.9M | −$13.2M | −25.89% | +12.66% |
| Q3 2018 | 2018-09-29 | $52.3M | $41.4M | +382.32% | +17.61% |
| Q2 2018 | 2018-06-30 | $34.0M | −$16.1M | −32.18% | +11.27% |
| Q1 2018 | 2018-03-31 | $16.6M | $18.1M | — | +5.67% |
| Q4 2017 | 2017-12-30 | $51.1M | $2.6M | +5.32% | — |
| Q3 2017 | 2017-09-30 | $10.8M | −$10.5M | −49.31% | +4.14% |
| Q2 2017 | 2017-07-01 | $50.1M | $20.3M | +68.09% | +19.50% |
| Q1 2017 | 2017-04-01 | −$1.5M | −$6.0M | — | — |
| Q4 2016 | 2016-12-31 | $48.5M | $18.8M | +63.37% | — |
| Q3 2016 | 2016-10-01 | $21.4M | −$281,000 | −1.30% | — |
| Q2 2016 | 2016-07-02 | $29.8M | $11.1M | +59.69% | — |
| Q1 2016 | 2016-04-02 | $4.5M | −$13.2M | −74.60% | — |
| Q4 2015 | 2016-01-02 | $29.7M | −$947,000 | −3.09% | — |
| Q3 2015 | 2015-10-03 | $21.7M | −$11.3M | −34.33% | — |
| Q2 2015 | 2015-07-04 | $18.7M | −$987,000 | −5.02% | — |
| Q1 2015 | 2015-04-04 | $17.7M | $16.2M | +1089.19% | — |
| Q4 2014 | 2015-01-03 | $30.6M | −$1.9M | −5.90% | — |
| Q3 2014 | 2014-09-27 | $33.0M | $19.0M | +136.40% | — |
| Q2 2014 | 2014-06-28 | $19.7M | −$5.2M | −21.06% | — |
| Q1 2014 | 2014-03-29 | $1.5M | −$17.9M | −92.33% | — |
| Q4 2013 | 2013-12-28 | $32.6M | $5.0M | +18.12% | — |
| Q3 2013 | 2013-09-28 | $14.0M | −$2.4M | −14.47% | — |
| Q2 2013 | 2013-06-29 | $24.9M | $4.8M | +24.00% | — |
| Q1 2013 | 2013-03-30 | $19.4M | −$983,000 | −4.81% | — |
| Q4 2012 | 2012-12-29 | $27.6M | $13.0M | +89.36% | — |
| Q3 2012 | 2012-09-29 | $16.3M | −$3.0M | −15.49% | — |
| Q2 2012 | 2012-06-30 | $20.1M | $11.3M | +129.84% | — |
| Q1 2012 | 2012-03-31 | $20.4M | $3.5M | +21.03% | — |
| Q4 2011 | 2011-12-31 | $14.6M | −$6.3M | −30.37% | — |
| Q3 2011 | 2011-10-01 | $19.3M | — | — | — |
| Q2 2011 | 2011-07-02 | $8.7M | — | — | — |
| Q1 2011 | 2011-04-02 | $16.9M | — | — | — |
| Q3 2010 | 2010-10-02 | $20.9M | — | — | — |
Usana Health Sciences free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $145.3M to $8.5M, a compound annual decline of 43.29%. Usana Health Sciences's latest reported quarter, Q2 2026, generated $20.2M in free cash flow, an increase of 180.41% year over year.
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
How free cash flow is calculated
TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Usana Health Sciences filings at SEC.gov ↗